News Sanofi names ex-Roche exec Fontoura as R&D chief Paulo Fontoura, currently chief medical officer of Xaira Therapeutics, will replace Houmab Ashrafian as Sanofi's R&D head on 1st September.
News UK will be first market for Sanofi's subcutaneous Sarclisa Sanofi's on-body injector version of multiple myeloma therapy Sarclisa has been cleared in the UK, which will be the first market for the product.
News Sanofi abandons phase 3 trial of neurology drug riliprubart Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.
Digital How pharma and start-ups are working together for AI success At the PharmStars Pharmtech Innovation Summit in Boston, start-up founders and pharma executives shared the stage to share lessons on AI deployment.
News November date set for FDA decision on Sanofi's Gaucher drug The FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.
News Sanofi says drug for rare disease AATD tops standard care After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.